Cardinal and Cadenza Studies for Cold Agglutinin Disease (CAD)
These two ongoing studies are for patients with troublesome Cold Agglutinin Disease, resulting in anaemia or thrombosis due to so-called ‘cold haemolysis’, that may or may not require transfusions. The treatment consists of infusions of an antibody treatment called sutimlimab that targets part of the immune system called the ‘complement system’ which is instrumental in cold haemolysis.
The Cardinal study has now closed to recruitment.
The Cadenza study is still recruiting.
Another trial of a new generation complement anti-body is due to open at University College London Hospitals (UCLH) shortly.